2022
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasis
2021
The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
Salazar MC, Canavan ME, Walters SL, Chilakamarry S, Ermer T, Blasberg JD, Yu JB, Gross CP, Boffa DJ. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clinical And Research Reports 2021, 2: 100143. PMID: 34590002, PMCID: PMC8474228, DOI: 10.1016/j.jtocrr.2021.100143.Peer-Reviewed Original ResearchStage I NSCLCWedge resectionSurveillance EpidemiologyMortality riskHigh riskSurvival advantageLife expectancyNational Cancer Institute's Surveillance EpidemiologyEnd Results-MedicareTreatment-naive patientsEarly-stage NSCLCRetrospective cohort studySuperior local controlShort life expectancyLife expectancy decreasesPerioperative complicationsCohort studyComorbid conditionsLung parenchymaLobectomyCox modelReasonable optionPatientsNSCLCLocal control
2019
Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection
Harmon S, Seder CW, Chen S, Traynor A, Jeraj R, Blasberg JD. Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection. Journal Of Thoracic Disease 2019, 11: 1106-1116. PMID: 31179052, PMCID: PMC6531752, DOI: 10.21037/jtd.2019.04.46.Peer-Reviewed Original ResearchDisease-free survivalSquamous cell carcinomaNon-small cell lung cancer patientsStandardized uptake valueCell lung cancer patientsEarly-stage NSCLCLung cancer patientsDisease recurrenceAnatomic resectionOverall survivalCancer patientsF-fluorodeoxyglucose positron emission tomography/computerized tomographyEarly stage non-small cell lung cancer patientsStage I/II NSCLC patientsPositron emission tomography/computerized tomographyCox proportional hazards regressionFDG PET/CTTomography/computerized tomographyQuantitative FDG-PET/CTPathologic node statusYears of resectionPreoperative risk factorsHigh-risk patientsSignificant univariate predictorsPrimary tumor volume
2010
Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer
Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2010, 28: 936-941. PMID: 20085934, PMCID: PMC2834433, DOI: 10.1200/jco.2009.25.5711.Peer-Reviewed Original ResearchConceptsEarly-stage NSCLCPlasma osteopontin levelsPlasma OPN levelsOPN levelsEnzyme-linked immunosorbent assayPlasma OPNOsteopontin levelsWeeks postsurgeryElevated Plasma Osteopontin LevelsCell lung cancer correlatesUse of thoracotomyCell lung cancerLung cancer correlatesCancer-free smokersResectable NSCLCPerioperative eventsTumor characteristicsPresurgery levelsRecurrence rateValidation cohortLung cancerCancer correlatesTherapeutic responseNSCLCIndependent cohort